Loading organizations...
Loading organizations...
Intracellular delivery of biologics for treating devastating diseases.
Entrada Therapeutics has raised $175.0M across 2 funding rounds.
Entrada Therapeutics has raised $175.0M in total across 2 funding rounds.
Entrada Therapeutics has raised $175.0M in total across 2 funding rounds.
Entrada Therapeutics's investors include Wellington Management, Kush Parmar, Agent Capital, CureDuchenne Ventures, Goldman Sachs, Greenspring Associates, MPM Capital, MRL Ventures Fund, Point72, Qatar Investment Authority, Redmile Group, Roche.
Entrada Therapeutics has raised $175.0M across 2 funding rounds. Most recently, it raised $116.0M Series B in March 2021.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Mar 31, 2021 | $116.0M Series B | Wellington Management | Kush Parmar, Agent Capital, CureDuchenne Ventures, Goldman Sachs, Greenspring Associates, MPM Capital, MRL Ventures Fund, Point72, Qatar Investment Authority, Redmile Group, Roche, TCGX, Undisclosed Global Investment Firm |
| Dec 18, 2018 | $59.0M Series A | Kush Parmar, Todd Foley | Agent Capital, Christine Brennan, Anja Harmeier |